The prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer

Chin, Stephanie; Trinkaus, Martina; Simmons, Cortnie R.; Flynn, C.; Bolivar, Ricardo; Clemons, M

doi:10.1200/jco.2008.26.15_suppl.20551

Cited by 13 publications

(32 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Genitourinary symptoms affect around 50%-75% of women taking adjuvant endocrine therapy for breast cancer (Baumgart et al, 2011;Chin et al, 2009;Lester, Bernhard, & Ryan-wenger, 2012;Trinkaus, Chin, Wolfman, Simmons, & Clemons, 2008). Symptoms may include (but are not limited to) vaginal dryness, vaginal soreness, urinary urgency, burning and incontinence and are likely due to the antioestrogenic effect of adjuvant endocrine therapy (Chin et al, 2009;Donovan, Boyington, Ismail-Khan, & Wyman, 2012;Lester et al, 2012). Research on the impact of genitourinary symptoms in women with breast cancer is relatively scarce, and most work has typically focused on quantitative outcomes such as frequency and grade of symptoms.…”

mentioning

confidence: 99%

Exploring knowledge, attitudes and experience of genitourinary symptoms in women with early breast cancer on adjuvant endocrine therapy

et al. 2018

View full text Add to dashboard Cite

Clinical trials of adjuvant endocrine therapy in women with early breast cancer have consistently reported that genitourinary symptoms are common. However, little is known about women's experiences of genitourinary symptoms, their views about the symptoms and how they impact on their lives. The aim of this study was to explore knowledge, attitudes and experiences of genitourinary symptoms among women receiving adjuvant endocrine therapy for early breast cancer. Thirty-two semi-structured interviews were conducted and subjected to a rigorous qualitative analysis. Genitourinary symptoms were commonly reported to negatively impact on personal, social and physical activities, were often attributed to anxiety and stress and were a source of embarrassment. Women also commented on the limited information available or provided regarding the potential genitourinary adverse effects of adjuvant endocrine therapy. There was a general lack of awareness that their symptoms could be associated with or exacerbated by adjuvant endocrine therapy. Women indicated a preference to receive information and advice about potential management options from either their general practitioner or specialist. These findings underscore the importance of improving communication and increasing awareness among both clinicians and patients about the potential impact of adjuvant endocrine therapy on genitourinary symptoms.

show abstract

mentioning

confidence: 99%

Exploring knowledge, attitudes and experience of genitourinary symptoms in women with early breast cancer on adjuvant endocrine therapy

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Especial atención merecen las pacientes que padecen cáncer ginecológico estrógeno-dependiente (mama, ovario, endometrio), las cuales presentan un elevado riesgo de síntomas importantes de AVV y disfunción sexual, especialmente en mujeres jóvenes (113)(114)(115)(116)(117)(118)(119). La literatura ha demostrado un incremento en la incidencia y progresión de los síntomas genitourinarios consecuencia de la quimioterapia, radioterapia y de la terapia endocrina.…”

Section: Discussionunclassified

Tratamiento del síndrome genitourinario de la menopausia mediante láser fraccionado CO2: una opción terapéutica emergente

T¹,

G²,

J³

et al. 2016

Rev. chil. obstet. ginecol.

View full text Add to dashboard Cite

RESUMENEstudios recientes han demostrado que el láser fraccionado es una opción terapéutica no hormonal efectiva, sencilla, bien tolerada y sin efectos adversos, para el tratamiento del Síndrome Genitourinario de la Menopausia. La reacción térmica originada produce la restauración del epitelio vaginal, un proceso de neocolagénesis y una mayor vascularización que favorece la llegada de nutrientes, reestableciéndose la estructura de la mucosa, su grosor y trofismo funcional, mejorando por tanto la sintomatología. No obstante, se precisan estudios a largo plazo, controlados, frente a estrógenos locales y otros tratamientos no hormonales para validar la duración de los efectos y la seguridad de las sucesivas aplicaciones. El objetivo de este trabajo es revisar la evidencia relacionada con esta terapia emergente. PALABRAS CLAVE: Láser, atrofia vaginal, síndrome genitourinario, menopausia SUMMARYRecent reported studies have demonstrated that non-invasive fractional laser is a valid, safe, effective and well tolerated therapeutic option, without adverse events to treat the Menopause Genitourinary Syndrome. The heat shock effect induces the increase of vaginal epithelium thickness, the new glycogen content and the vascular changes, improving the vaginal epithelium structure, functionality and menopausal symptoms. Nevertheless, duration of treatment effects and safety of repeated session are not clear enough. Further controlled long-term follow-up research on laser versus local estrogens and other non-hormonal therapies are needed. The objective of this paper is to review the scientific evidence related to this emergent treatment.

show abstract

“…Atrophic vaginitis is prevalent in menopausal women, but more so in postmenopausal breast cancer survivors [ 8 , 9 , 10 ]. Symptoms of atrophic vaginitis include vaginal dryness, dyspareunia, irritation of genital skin, pruritus, burning, vaginal discharge, and soreness [ 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ].…”

Section: Symptoms Of Atrophic Vaginitismentioning

confidence: 99%

“…Several objective findings on physical exam may be relevant. The gynecologic examination may reveal sparse vulvar hair, decreased subcutaneous fat within the mons pubis and labia majora, reduced volume of labia minora, retracted clitoris, and inadequate vaginal lubrication with a dry, shiny and pale introitus [ 5 , 7 , 8 , 14 ]. In research studies, samples of vaginal secretions can be obtained to determine vaginal pH, presence or absence of yeast, and parabasal cell level.…”

Section: Diagnosis Of Atrophic Vaginitismentioning

confidence: 99%

“…One such treatment side effect is atrophic vaginitis, caused by decreased levels of circulating estrogen to urinary and vaginal receptors [ 5 , 6 , 7 ]. Atrophic vaginitis is a survivorship issue that affects nearly 70% of postmenopausal breast cancer survivors as compared to 50% of postmenopausal women without breast cancer [ 8 , 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue

Lester

Pahouja

Andersen

et al. 2015

JPM

View full text Add to dashboard Cite

Management of breast cancer includes systematic therapies including chemotherapy and endocrine therapy can lead to a variety of symptoms that can impair the quality of life of many breast cancer survivors. Atrophic vaginitis, caused by decreased levels of circulating estrogen to urinary and vaginal receptors, is commonly experienced by this group. Chemotherapy induced ovarian failure and endocrine therapies including aromatase inhibitors and selective estrogen receptor modulators can trigger the onset of atrophic vaginitis or exacerbate existing symptoms. Symptoms of atrophic vaginitis include vaginal dryness, dyspareunia, and irritation of genital skin, pruritus, burning, vaginal discharge, and soreness. The diagnosis of atrophic vaginitis is confirmed through patient-reported symptoms and gynecological examination of external structures, introitus, and vaginal mucosa. Lifestyle modifications can be helpful but are usually insufficient to significantly improve symptoms. Non-hormonal vaginal therapies may provide additional relief by increasing vaginal moisture and fluid. Systemic estrogen therapy is contraindicated in breast cancer survivors. Continued investigations of various treatments for atrophic vaginitis are necessary. Local estrogen-based therapies, DHEA, testosterone, and pH-balanced gels continue to be evaluated in ongoing studies. Definitive results are needed pertaining to the safety of topical estrogens in breast cancer survivors.

show abstract

The prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer

Cited by 13 publications

References 0 publications

Exploring knowledge, attitudes and experience of genitourinary symptoms in women with early breast cancer on adjuvant endocrine therapy

Exploring knowledge, attitudes and experience of genitourinary symptoms in women with early breast cancer on adjuvant endocrine therapy

Tratamiento del síndrome genitourinario de la menopausia mediante láser fraccionado CO2: una opción terapéutica emergente

Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue

Contact Info

Product

Resources

About